CUMYL-CBMINACA
CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Germany in February 2020.[1]
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C22H25N3O |
| Molar mass | 347.462 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
- CUMYL-CBMICA
- CUMYL-CH-MEGACLONE
- CUMYL-CHMICA
- CUMYL-THPINACA
References
- "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
| Receptor (ligands) |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||
| Enzyme (modulators) |
| ||||||||||||
| Others |
| ||||||||||||
| |||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.